



Narcotics Control Bureau

Press Release

Date - 12.01.2026

- NCB Secures Major Conviction in Pseudoephedrine Diversion Case Involving Alps Life Sciences**

In a significant breakthrough against diversion of pharmaceutical precursors used in illicit drug manufacturing, the Narcotics Control Bureau (NCB) has secured conviction in a major case involving M/s Alps Life Sciences Pvt. Ltd., Sonipat, Haryana, and its senior functionaries. The case was investigated by the NCB Ahmedabad Zonal Unit and pertains to diversion of pseudoephedrine, a controlled substance under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.

Based on specific intelligence received in March 2023, NCB intercepted a container at Pipavav Port, Gujarat, which was destined for export to Africa. The consignment, originating from ICD Panchi, Sonipat, consisted of approximately 60 lakh pharmaceutical capsules declared as containing ephedrine/pseudoephedrine. During investigation, it was revealed that the consignment included three products—ALPCIT, COLDFIT and T-DOL. While ALPCIT legitimately contained pseudoephedrine, the other two products were falsely declared as containing the controlled substance.

Further investigation established that approximately 6 kilograms of pseudoephedrine, purportedly shown as consumed in the manufacture of COLDFIT and T-DOL, had in fact been clandestinely diverted. Pseudoephedrine is a critical precursor used in the illicit manufacture of methamphetamine, a psychotropic substance posing serious threats to public health and national security.

The investigation revealed deliberate falsification of manufacturing and export records and active involvement of senior company officials. The accused arrested in the case were Sh. Sumit Kumar, Managing Director, Sh. Sumit Kumar, Store In-charge, and Sh. Dhanesh Chamoli, Authorized Chief Chemist-cum-Production Manager. The company, M/s Alps Life Sciences Pvt. Ltd., was also arraigned as an accused. The case was registered under Sections 9A read with 25A, 26, 29, 35 and 38 of the NDPS Act, 1985, and relevant provisions of the NDPS (Regulation of Controlled Substances) Order, 2013.

During the course of investigation and trial, the accused sought bail from various judicial fora, including the Hon'ble Supreme Court of India. However, considering the seriousness of the offence, the transnational ramifications of precursor diversion, and the strong evidentiary foundation laid by NCB, the bail pleas were not accepted, underscoring the gravity of the crime.

The complaint against the accused persons and the company was filed before the Hon'ble Court at Savarkundla, District Amreli, Gujarat, on 24 November 2023. After detailed trial, the Hon'ble Court, vide judgment dated 12 January 2026, convicted all three accused and sentenced them to seven years of rigorous imprisonment along with a fine of ₹1.5 lakh each. The company, M/s Alps Life Sciences Pvt. Ltd., was also convicted and fined ₹1.5 lakh.

This conviction sends a strong message that diversion of pharmaceutical precursors and misuse of legitimate drug manufacturing channels will not be tolerated. The successful outcome reflects NCB's professional investigation, inter-agency coordination and sustained legal follow-up, and reinforces its commitment to dismantling drug supply chains.

NCB reiterates its resolve to achieve the national vision of Drug-Free India (Nasha Mukt Bharat) and seeks active public cooperation. Information related to sale, transport or trafficking of narcotics can be shared through the MANAS – National Narcotics Helpline (Toll Free No. 1933). The identity of informers is kept strictly confidential.

(Press Release Id -12/01/2026-NCB/ Conviction)